Chronically elevated fasting blood glucose levelsor recurrent, excessive spikes in glucose levels after meals can lead to devastating long-term consequences such as heart disease and stroke, blindness, kidney failure, neuropathy, liver disease, and even cancer (Ahmadieh 2014
[PubMed] Challa, F., Getahun, T., Sileshi, M., Nigassie, B., Geto, Z., Ashibire, G., Gelibo, T., Teferra, S., Seifu, D., Sitotaw, Y., Bekele, A., Abate, E., & Baye, K
Payment and support quality complete the picture
Pascal Soriot, CEO of the company noted he was excited about the acceleration of the companys cardiometabolic and obesity pipeline with the licensing agreement for ECC5004, a potential best-in-class oral GLP-1RA. ECC5004 has an oral formulation, in contrast to Novo Nordisks Wegovy (semaglutide) and the recently approved Lillys Zepbound (tirzepatide), which are injectables